Integration of PARP-inhibitors in ovarian cancer therapy.
Antonella PietragallaFrancesca CiccaroneCamilla NeroGiovanni ScambiaDomenica LorussoGennaro DanielePublished in: Exploration of targeted anti-tumor therapy (2020)
Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients.
Keyphrases
- dna damage
- dna repair
- phase ii
- end stage renal disease
- clinical trial
- ejection fraction
- chronic kidney disease
- open label
- acute lymphoblastic leukemia
- newly diagnosed
- acute myeloid leukemia
- oxidative stress
- diffuse large b cell lymphoma
- peritoneal dialysis
- transcription factor
- machine learning
- big data
- young adults
- squamous cell
- deep learning
- patient reported
- study protocol
- placebo controlled